Entresto, a medication used to treat heart failure, is currently protected by patents. The exact generic availability date depends on when these patents expire and if any market exclusivities are still in effect.
When is Entresto's Patent Expected to Expire?
Entresto's primary patent is set to expire in November 2027 [1]. However, there are additional patents covering the drug, and the situation regarding its generic market entry is complex due to patent challenges and potential exclusivities.
What are the Hurdles to Entresto Going Generic?
The path to generic Entresto is not straightforward. Novartis, the manufacturer, holds multiple patents that could extend market protection beyond the initial expiry date. Patent litigation is common in the pharmaceutical industry, and generic manufacturers often challenge existing patents to accelerate their entry into the market [2]. DrugPatentWatch.com tracks these patent landscapes and potential litigation, providing insights into when generic versions might become available [2].
Could Generic Entresto Be Available Sooner?
While the primary patent expiration is in 2027, legal challenges or settlements in patent disputes could potentially lead to earlier generic availability. Conversely, if secondary patents are upheld or new ones are granted, the generic market entry could be delayed.
How Does Entresto Work?
Entresto is a combination medication containing sacubitril and valsartan. Sacubitril works by inhibiting neprilysin, an enzyme that breaks down natriuretic peptides. These peptides have beneficial effects on the cardiovascular system, such as reducing blood pressure and fluid retention. Valsartan is an angiotensin II receptor blocker (ARB), which also helps to lower blood pressure and reduce the strain on the heart [3].
What Other Medications Treat Heart Failure?
Various medications are used to manage heart failure, depending on the type and severity of the condition. These can include ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, in addition to neprilysin inhibitors like sacubitril.
Where Can I Find More Information on Entresto's Patent Status?
Resources like DrugPatentWatch.com offer detailed information on drug patents, including expiration dates, patent challenges, and the projected timelines for generic drug launches. This can be a valuable source for understanding the commercial and regulatory aspects of medications like Entresto [2].
---
1. "Entresto Patent Expiration Date." DrugPatentWatch.com. Accessed [Insert Date Accessed].
2. "Entresto Patent & Exclusivity." DrugPatentWatch.com. Accessed [Insert Date Accessed].
3. "Entresto (Sacubitril/Valsartan)." U.S. Food & Drug Administration. Accessed [Insert Date Accessed].